165 related articles for article (PubMed ID: 17371824)
1. Evolution of resistant M414T mutants among hepatitis C virus replicon cells treated with polymerase inhibitor A-782759.
Lu L; Mo H; Pilot-Matias TJ; Molla A
Antimicrob Agents Chemother; 2007 Jun; 51(6):1889-96. PubMed ID: 17371824
[TBL] [Abstract][Full Text] [Related]
2. Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.
Mo H; Lu L; Pilot-Matias T; Pithawalla R; Mondal R; Masse S; Dekhtyar T; Ng T; Koev G; Stoll V; Stewart KD; Pratt J; Donner P; Rockway T; Maring C; Molla A
Antimicrob Agents Chemother; 2005 Oct; 49(10):4305-14. PubMed ID: 16189112
[TBL] [Abstract][Full Text] [Related]
3. In vitro resistance study of AG-021541, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.
Shi ST; Herlihy KJ; Graham JP; Fuhrman SA; Doan C; Parge H; Hickey M; Gao J; Yu X; Chau F; Gonzalez J; Li H; Lewis C; Patick AK; Duggal R
Antimicrob Agents Chemother; 2008 Feb; 52(2):675-83. PubMed ID: 18070954
[TBL] [Abstract][Full Text] [Related]
4. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479.
Ali S; Leveque V; Le Pogam S; Ma H; Philipp F; Inocencio N; Smith M; Alker A; Kang H; Najera I; Klumpp K; Symons J; Cammack N; Jiang WR
Antimicrob Agents Chemother; 2008 Dec; 52(12):4356-69. PubMed ID: 18838588
[TBL] [Abstract][Full Text] [Related]
5. Resistance profile of a hepatitis C virus RNA-dependent RNA polymerase benzothiadiazine inhibitor.
Nguyen TT; Gates AT; Gutshall LL; Johnston VK; Gu B; Duffy KJ; Sarisky RT
Antimicrob Agents Chemother; 2003 Nov; 47(11):3525-30. PubMed ID: 14576112
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796.
Howe AY; Cheng H; Johann S; Mullen S; Chunduru SK; Young DC; Bard J; Chopra R; Krishnamurthy G; Mansour T; O'Connell J
Antimicrob Agents Chemother; 2008 Sep; 52(9):3327-38. PubMed ID: 18559648
[TBL] [Abstract][Full Text] [Related]
7. A cell-based assay for RNA synthesis by the HCV polymerase reveals new insights on mechanism of polymerase inhibitors and modulation by NS5A.
Ranjith-Kumar CT; Wen Y; Baxter N; Bhardwaj K; Cheng Kao C
PLoS One; 2011; 6(7):e22575. PubMed ID: 21799903
[TBL] [Abstract][Full Text] [Related]
8. Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.
Chen CM; He Y; Lu L; Lim HB; Tripathi RL; Middleton T; Hernandez LE; Beno DW; Long MA; Kati WM; Bosse TD; Larson DP; Wagner R; Lanford RE; Kohlbrenner WE; Kempf DJ; Pilot-Matias TJ; Molla A
Antimicrob Agents Chemother; 2007 Dec; 51(12):4290-6. PubMed ID: 17908950
[TBL] [Abstract][Full Text] [Related]
9. Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
Herlihy KJ; Graham JP; Kumpf R; Patick AK; Duggal R; Shi ST
Antimicrob Agents Chemother; 2008 Oct; 52(10):3523-31. PubMed ID: 18694956
[TBL] [Abstract][Full Text] [Related]
10. A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors.
Chase R; Skelton A; Xia E; Curry S; Liu S; McMonagle P; Huang HC; Tong X
Antiviral Res; 2009 Nov; 84(2):178-84. PubMed ID: 19747948
[TBL] [Abstract][Full Text] [Related]
11. PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
Lam AM; Murakami E; Espiritu C; Steuer HM; Niu C; Keilman M; Bao H; Zennou V; Bourne N; Julander JG; Morrey JD; Smee DF; Frick DN; Heck JA; Wang P; Nagarathnam D; Ross BS; Sofia MJ; Otto MJ; Furman PA
Antimicrob Agents Chemother; 2010 Aug; 54(8):3187-96. PubMed ID: 20516278
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor.
Kati W; Koev G; Irvin M; Beyer J; Liu Y; Krishnan P; Reisch T; Mondal R; Wagner R; Molla A; Maring C; Collins C
Antimicrob Agents Chemother; 2015 Mar; 59(3):1505-11. PubMed ID: 25534735
[TBL] [Abstract][Full Text] [Related]
13. Allele-specific real-time PCR system for detection of subpopulations of genotype 1a and 1b hepatitis C NS5B Y448H mutant viruses in clinical samples.
Bae AS; Ku KS; Miller MD; Mo H; Svarovskaia ES
J Clin Microbiol; 2011 Sep; 49(9):3168-74. PubMed ID: 21715590
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052.
Wang C; Huang H; Valera L; Sun JH; O'Boyle DR; Nower PT; Jia L; Qiu D; Huang X; Altaf A; Gao M; Fridell RA
Antimicrob Agents Chemother; 2012 Mar; 56(3):1350-8. PubMed ID: 22214777
[TBL] [Abstract][Full Text] [Related]
15. Genotypic and phenotypic analyses of hepatitis C virus from patients treated with JTK-853 in a three-day monotherapy.
Ogura N; Toyonaga Y; Ando I; Hirahara K; Shibata T; Turcanu G; Pai S; Yee K; Gerhardt B; Rodriguez-Torres M; Noguchi T
Antimicrob Agents Chemother; 2013 Jan; 57(1):436-44. PubMed ID: 23129048
[TBL] [Abstract][Full Text] [Related]
16. A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populations.
Middleton T; He Y; Pilot-Matias T; Tripathi R; Lim BH; Roth A; Chen CM; Koev G; Ng TI; Krishnan P; Pithawalla R; Mondal R; Dekhtyar T; Lu L; Mo H; Kati WM; Molla A
J Virol Methods; 2007 Nov; 145(2):137-45. PubMed ID: 17604129
[TBL] [Abstract][Full Text] [Related]
17. Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus.
Le Pogam S; Kang H; Harris SF; Leveque V; Giannetti AM; Ali S; Jiang WR; Rajyaguru S; Tavares G; Oshiro C; Hendricks T; Klumpp K; Symons J; Browner MF; Cammack N; Nájera I
J Virol; 2006 Jun; 80(12):6146-54. PubMed ID: 16731953
[TBL] [Abstract][Full Text] [Related]
18. Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.
Shi ST; Herlihy KJ; Graham JP; Nonomiya J; Rahavendran SV; Skor H; Irvine R; Binford S; Tatlock J; Li H; Gonzalez J; Linton A; Patick AK; Lewis C
Antimicrob Agents Chemother; 2009 Jun; 53(6):2544-52. PubMed ID: 19307358
[TBL] [Abstract][Full Text] [Related]
19. Preclinical characterization of JTK-853, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.
Ando I; Adachi T; Ogura N; Toyonaga Y; Sugimoto K; Abe H; Kamada M; Noguchi T
Antimicrob Agents Chemother; 2012 Aug; 56(8):4250-6. PubMed ID: 22615294
[TBL] [Abstract][Full Text] [Related]
20. [Replication of the subgenomic hepatitis C virus replicon in the presence of the NS3 protease inhibitors: a stochastic model].
Ivanisenko NV; Mishchenko EL; Akberdin IR; Demenkov PS; Likhoshvai VA; Kozlov KN; Todorov DI; Samsonova MG; Samsonov AM; Kolchanov NA; Ivanisenko VA
Biofizika; 2013; 58(5):758-74. PubMed ID: 25481944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
